Rhode Island Patent of the Month – November 2023

Rhodes Technologies Inc. has introduced a game-changing pharmaceutical creation that takes a fresh approach to pain relief. This innovative composition brings a new perspective to managing discomfort, steering away from conventional opioid solutions.

Standard opioid formulations result in extensive potential side effects including rampant abuse and addiction. Rhodes Technologies’ formulation attempts to reduce the abuse potential. Their opioid ketal compound is delivered by a friendly carrier. The approach works for various compounds including oxycodone, hydrocodone and more.

What’s truly impressive about this creation is its dual action. While it targets pain, it importantly takes a stand against the potential risks associated with traditional opioids, such as abuse and side effects. In a world where finding effective, safe pain relief is crucial, this innovation paves the way for better patient care and safer pain management solutions.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts